Why Is Alumis Stock Falling Monday?

Like
Comment
Favorite

Why Is Alumis Stock Falling Monday?

Benzinga_recent_news03-31

Alumis on Saturday shared results from its Phase 3 ONWARD1 and ONWARD2 trials for envudeucitinib, a treatment for moderate-to-severe plaque psoriasis. The data revealed that approximately three out of...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2623340604?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/30/Medical-Research_0.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-03-31 00:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623340604","market":"sh","top_or_hot":-1,"title":"Why Is Alumis Stock Falling Monday?","media":"Benzinga_recent_news","content":"<div>\n<p>Alumis on Saturday shared results from its Phase 3 ONWARD1 and ONWARD2 trials for envudeucitinib, a treatment for moderate-to-severe plaque psoriasis.\nThe data revealed that approximately three out of...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/03/51546429/why-is-alumis-stock-falling-monday\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Alumis Stock Falling Monday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Alumis Stock Falling Monday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-31 00:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/03/51546429/why-is-alumis-stock-falling-monday><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alumis on Saturday shared results from its Phase 3 ONWARD1 and ONWARD2 trials for envudeucitinib, a treatment for moderate-to-severe plaque psoriasis.\nThe data revealed that approximately three out of...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/03/51546429/why-is-alumis-stock-falling-monday\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/03/51546429/why-is-alumis-stock-falling-monday","article_id":"2623340604","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/30/Medical-Research_0.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/03/51546429/why-is-alumis-stock-falling-monday","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2623340604","pubTimestamp":1774889640,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"ALMS stock drops 11% as investors lock in a 239% yearly gain. Analyze the support levels and technical indicators for Alumis Inc. (NASDAQ).","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4217":"自存仓储房地产信托","ALMS":"Alumis Inc.","SMA":"Smartstop Self Storage REIT Inc"},"translate_title":"为什么Alumis股票周一下跌？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMA":1,"ALMS":1.5},"content_text":"Alumis on Saturday shared results from its Phase 3 ONWARD1 and ONWARD2 trials for envudeucitinib, a treatment for moderate-to-severe plaque psoriasis.\nThe data revealed that approximately three out of four patients achieved clear or almost clear scalp psoriasis by Week 24, with significant improvements in quality of life and itch relief appearing as early as Week 4.\nEnvudeucitinib demonstrated encouraging skin clearance.\nPsoriasis Area and Severity Index (PASI) 90 responses were achieved by 59.9% and 53.1% of envudeucitinib patients at Week 16 (and by 4.8% and 4.3% of placebo patients), increasing to 68.0% and 62.1% at Week 24.\nPASI 100 responses followed a similar trajectory, with 29.4% and 27.7% of envudeucitinib patients achieving complete skin clearance at Week 16 (as compared to 0.9% and 0.9% of placebo patients), rising to 41.0% and 39.5% at Week 24.\nQuality‑of‑life improvements and itch relief emerged ahead of PASI 90 skin clearance, and clear or almost clear scalp psoriasis emerged by Week 4, highlighting envudeucitinib’s early onset and broad clinical benefit.\nThe company released topline data in January.\nIn addition, the company plans to submit a New Drug Application to the U.S. Food and Drug Administration (FDA) in the second half of this year, highlighting its commitment to advancing this treatment.\nThe stock is currently trading 20.3% below its 20-day simple moving average (SMA) and 21.4% below its 50-day SMA, indicating a bearish trend in the short term.\nHowever, it is trading 14.2% above its 100-day SMA, suggesting some longer-term strength, and has increased by 239.66% over the past 12 months, reflecting a significant upward trend in the longer timeframe.\nThe RSI is at 45.35, which is considered neutral territory, indicating that the stock is neither overbought nor oversold. Meanwhile, MACD shows a value of -0.4299, with the signal line at -0.1946, indicating bearish pressure as the MACD is below the signal line.\nThe combination of neutral RSI and bearish MACD suggests mixed momentum, reflecting uncertainty in the stock’s immediate direction.\nAnalyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $33.42. Recent analyst moves include:\nALMS Stock Price Activity: Alumis shares were down 11.69% at $21.90 at the time of publication on Monday, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}